Annexon Ownership | Who Owns Annexon?
Annexon Ownership Summary
Annexon is owned by 100.54% institutional investors, 0.47% insiders. Redmile group is the largest institutional shareholder, holding 9.38% of ANNX shares. BB Biotech AG Ord is the top mutual fund, with 3.46% of its assets in Annexon shares.
ANNX Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Annexon | 100.54% | 0.47% | -1.01% |
| Sector | Healthcare Stocks | 35.34% | 11.88% | 52.77% |
| Industry | Biotech Stocks | 35.37% | 11.83% | 52.80% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Redmile group | 14.55M | 9.38% | $80.61M |
| Blackrock funding, inc. /de | 10.94M | 7.05% | $60.60M |
| Fmr | 10.64M | 6.86% | $58.92M |
| Bvf inc/il | 8.70M | 5.61% | $48.19M |
| Blackrock | 6.59M | 5.37% | $32.28M |
| Alerce investment management | 7.41M | 5.29% | $37.99M |
| Vanguard group | 7.75M | 5.20% | $38.92M |
| State street | 6.92M | 4.46% | $38.33M |
| Bain capital life sciences investors | 5.21M | 3.36% | $28.88M |
| Bellevue group | 5.16M | 3.33% | $28.57M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Alerce investment management | 7.41M | 66.89% | $37.99M |
| Redmile group | 14.55M | 5.34% | $80.61M |
| Mak capital one | 4.72M | 3.86% | $26.17M |
| Great point partners | 2.50M | 3.18% | $13.85M |
| Bain capital life sciences investors | 5.21M | 2.60% | $28.88M |
| Palo alto investors lp | 2.95M | 2.50% | $16.33M |
| Opaleye management | 2.33M | 1.70% | $12.92M |
| Bvf inc/il | 8.70M | 1.54% | $48.19M |
| Tfg asset management gp | 1.29M | 1.39% | $7.16M |
| Bellevue group | 5.16M | 0.68% | $28.57M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Redmile group | 14.55M | 5.34% | 4.50M |
| Siren | 3.96M | 0.61% | 3.96M |
| Great point partners | 2.50M | 3.18% | 2.50M |
| State street | 6.92M | 0.00% | 2.27M |
| Blackrock funding, inc. /de | 10.94M | 0.00% | 1.98M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Sio capital management | - | - | -4.10M |
| Candriam s.c.a. | - | - | -2.53M |
| Longaeva partners | 620.40K | 0.13% | -2.48M |
| Logos global management lp | - | - | -2.41M |
| Gmt capital | - | - | -1.91M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Siren | 3.96M | 0.61% | 3.96M | $21.93M |
| Great point partners | 2.50M | 3.18% | 2.50M | $13.85M |
| Y-intercept (hong kong) | 1.32M | 0.14% | 1.32M | $7.31M |
| Vanguard fiduciary trust | 888.55K | 0.00% | 888.55K | $4.92M |
| Ensign peak advisors | 625.10K | 0.01% | 625.10K | $3.46M |
Sold Out
| Holder | Change |
|---|---|
| National bank of canada /fi/ | -2.00 |
| Northwestern mutual wealth management | -4.00 |
| Nelson, van denburg & campbell wealth management group | -9.00 |
| Quadrant capital group | -34.00 |
| Lindbrook capital | -83.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 224 | 27.27% | 155,946,810 | 13.91% | 100 | 1.19% | 153 | 37.84% | 48 | 54.84% |
| Dec 31, 2025 | 86 | -42.67% | 42,294,902 | -58.29% | 28 | 0.61% | 51 | -40.00% | 17 | -54.05% |
| Sep 30, 2025 | 144 | 16.13% | 101,348,566 | 4.74% | 68 | 1.60% | 80 | 26.98% | 36 | 5.88% |
| Jun 30, 2025 | 129 | -15.13% | 99,605,116 | -0.16% | 67 | 1.48% | 67 | -15.19% | 34 | -17.07% |
| Mar 31, 2025 | 10 | -93.59% | 26,197,503 | -76.64% | 17 | 0.28% | 4 | -95.51% | - | -100.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| BB Biotech AG Ord | 5.16M | 3.46% | - |
| Fidelity Select Biotechnology | 4.73M | 2.91% | - |
| Vanguard Total Stock Mkt Idx Inv | 4.31M | 2.69% | - |
| State Street® SPDR® S&P® Biotech ETF | 4.26M | 2.62% | -42.10K |
| Vanguard US Total Market Shares ETF | 2.83M | 2.58% | - |
| Fidelity Growth Compy Commingled Pl O | 2.37M | 2.25% | - |
| SPDR® S&P Biotech ETF | 2.32M | 2.11% | -14.13K |
| iShares Russell 2000 ETF | 3.12M | 1.92% | 26.27K |
| Candriam Eqs L Biotech C USD Cap | 2.58M | 1.73% | 49.35K |
| Fidelity Growth Compy Commingled Pl S | 1.85M | 1.68% | -604.61K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| May 11, 2026 | Carson William H. | - | Buy | $46.24K |
| Apr 10, 2026 | Carson William H. | - | Buy | $49.60K |
| Mar 10, 2026 | Carson William H. | - | Buy | $45.36K |
| Mar 02, 2026 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Sell | $31.60K |
| Mar 02, 2026 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | $23.52K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | 2 | - |
| 2026 Q1 | 1 | 10 |
| 2025 Q4 | 9 | - |
| 2025 Q3 | 3 | 3 |
| 2025 Q2 | 1 | - |
ANNX Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools